The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of 64Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC).
 
Toshihiro Horii
No Relationships to Disclose
 
Mitsuyoshi Yoshimoto
No Relationships to Disclose
 
Akinori Kobayashi
No Relationships to Disclose
 
Chihiro Kondo
No Relationships to Disclose
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Chikako Funasaka
No Relationships to Disclose
 
Hiromichi Nakajima
Employment - Otsuka (I)
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Yasutoshi Kuboki
Honoraria - Kyowa Kirin; Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Incyte; Noile-Immune Biotech, Inc; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); Incyte (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte
 
Kimiteru Ito
No Relationships to Disclose
 
Masato Murakami
Employment - PDRadiopharma Inc; PeptiDream Inc
Leadership - PDRadiopharma Inc; PeptiDream Inc
Stock and Other Ownership Interests - PeptiDream Inc
 
Shoko Ito
Employment - PeptiDream Inc
Stock and Other Ownership Interests - PeptiDream
 
Tomoaki Higuchi
Employment - PeptiDream Inc
Stock and Other Ownership Interests - PeptiDream
 
Naoki Kanazawa
Employment - PDRadiopharma Inc.
Stock and Other Ownership Interests - Fujifilm
 
Yuichi Funase
Employment - PDRadiopharma Inc.
 
Daisuke Kano
No Relationships to Disclose
 
Akira Inagaki
No Relationships to Disclose
 
Saeko Mochinaga
No Relationships to Disclose
 
Hikari Inagawa
No Relationships to Disclose
 
Tatsushi Kobayashi
No Relationships to Disclose
 
Anri Inaki
Research Funding - PeptiDream